Premier (PINC)
(Delayed Data from NSDQ)
$19.50 USD
-0.26 (-1.32%)
Updated May 10, 2024 04:00 PM ET
After-Market: $19.51 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Price, Consensus and EPS Surprise
PINC 19.50 -0.26(-1.32%)
Will PINC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PINC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PINC
Here's What Key Metrics Tell Us About Premier (PINC) Q3 Earnings
Premier, Inc. (PINC) Q3 Earnings and Revenues Surpass Estimates
PINC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Premier (PINC) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
ModivCare (MODV) Reports Q1 Loss, Tops Revenue Estimates
Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?
Other News for PINC
Premier Inc. Hold Rating Maintained Amid Financial Uncertainty and GPO Economics Pressure
Premier, Inc. to Participate in BofA Securities Healthcare Conference on May 14, 2024
Unveiling 4 Analyst Insights On Premier
Premier, Inc. Announces Cross-Industry Initiative to Improve Diagnosis and Care for Chronic Kidney Disease
Premier price target lowered by $2 at Piper Sandler, here's why